Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18235520 | 0.94 | GLA (0.30) | GLA | |
| SCHEMBL18235506 | 0.92 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL18235512 | 0.92 | — | — | |
| SCHEMBL18235513 | 0.90 | ALDH1A1 (0.36) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL18239622 | 0.85 | NAAA (0.31) | — | |
| SCHEMBL18239571 | 0.82 | ALDH1A1 (0.34) | GLABTN3A1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL7620877 | 0.77 | ALDH1A1 (0.43) | GLAMEN1KMT2ABTN3A1ALDH1A1 | |
| SCHEMBL18239570 | 0.74 | CTSA (0.38) | GLAMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL18235515 | 0.74 | TSHR (0.50) | MEN1KMT2A | |
| SCHEMBL18235500 | 0.71 | GLA (0.37) | GLAMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988394-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | UGT2B7, UGT1A6, UGT1A1 | GLA 1396/4885MEN1 2175/4885KMT2A 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.